Bioreactivity of glutathionyl hydroquinone with implications to benzene toxicity

Glutathionyl hydroquinone (GHQ), a highly reactive metabolite of benzene, has been implicated as a causative intermediate of benzene toxicity. To substantiate, the bioreactivity of GHQ was investigated under in vitro and in vivo conditions using end points, characteristic of benzene toxicity. Under in vitro conditions, the presence of GHQ: (a) linearly increased the release of aldehydic products from L-glutamate or deoxyuridine at GHQ concentrations of 5-25 microM and from rat liver homogenates at GHQ concentrations of 50-250 microM; (b) cleaved plasmid pUC 18 supercoiled DNA through a single strand nick to yield open circular relaxed DNA, and through a double strand cut to give out linear DNA at GHQ concentrations of 25-200 microM, with evidence of protection by catalase and superoxide dismutase; and (c) induced cross-linking and polymerization of lymphocyte nuclear DNA through in situ generation of GHQ, which was protected by pretreatment of lymphocytes with N-ethylmaleimide. In vivo exposure of Swiss albino mice to GHQ (100 mg/kg, intraperitoneally once daily for 30 days) resulted in significant increase of liver weight and inhibition of mitotic index in the bone marrow. The other test parameters, namely spleen weight, hematological indices, hepatic sulphahydryl content and nonenzymatic lipid peroxidation, and chromosomal aberrations in the bone marrow were, however, unaffected by GHQ treatment. The observations indicate pro-oxidant and cytotoxic potential of GHQ, mediated by the reactive oxygen species generated during the course of its auto-oxidation. Bioreactivity of GHQ with cellular macromolecules in vitro and inhibition of mitotic index of bone marrow on in vivo exposure have relevance to benzene toxicity, although in situ generation of GHQ at the site of action appears critical in bringing about hematological and chromosomal effects that were probably spared due to rapid metabolic disposition and, consequently, poor bioavailability of intraperitoneally administered GHQ.